What Red Light Therapy Actually Is
Red light therapy—more formally termed photobiomodulation (PBM)—has moved from dermatology clinics into the homes of many families. As pediatricians, particularly those practicing within an integrative framework, we are increasingly asked to interpret this modality: what it is, what it does, and whether it has a legitimate role in pediatric care.
At its core, PBM refers to the therapeutic use of specific wavelengths of light, primarily in the red (approximately 620–700 nm) and near-infrared (700–1440 nm) spectrum, delivered through low-level lasers or light-emitting diodes (LEDs). Unlike ultraviolet radiation, these wavelengths do not damage DNA but instead penetrate tissue and interact with intracellular photoacceptors.
The most widely proposed mechanism involves mitochondrial signaling. Photons are absorbed by chromophores such as cytochrome c oxidase, leading to increased ATP production, modulation of reactive oxygen species, nitric oxide release, and downstream changes in gene expression. In physiologic terms, PBM is less about “healing energy” and more about altering cellular metabolism and inflammatory pathways.
Clinical Applications That Have Been Studied
The strongest evidence for PBM comes from dermatology and supportive oncology, with some overlap into pediatric care. A consistent pattern across the literature is that PBM is most effective in conditions characterized by localized inflammation, impaired healing, or altered cellular turnover.
Among the best-supported applications are oral mucositis, wound healing, alopecia, and herpes simplex infections, with several areas supported by randomized controlled trials and meta-analyses.
Of particular relevance to pediatrics is oral mucositis in children undergoing chemotherapy. Clinical trials demonstrate that PBM can reduce severity, shorten duration, and improve pain control—making it one of the most compelling pediatric use cases.
Wound healing is another area of consistent benefit, with studies showing enhanced collagen production, angiogenesis, and faster epithelialization. Acne treatment has also been studied, with moderate evidence suggesting reductions in inflammatory lesions through effects on sebaceous activity and bacterial pathways.
Across these applications, the unifying theme is that PBM appears to influence local tissue biology, rather than systemic physiology.
What Parents Are Hearing Online
In contrast to the relatively focused clinical evidence, the claims circulating in popular media are far broader. Families may encounter messaging that red light therapy can boost immunity, improve sleep, enhance brain development, treat autism or ADHD, or “detoxify” the body.
These claims often originate from plausible biologic mechanisms—particularly the central role of mitochondrial function—but extend far beyond what has been demonstrated in clinical studies. The extrapolation from cellular signaling to whole-body therapeutic effects is substantial and, at present, largely unsupported.
For pediatricians, this creates a familiar challenge: helping families distinguish between interventions that are biologically interesting and those that are clinically validated. PBM, at least for now, belongs more firmly in the former category when it comes to systemic or neurologic outcomes.
What the Evidence Actually Shows
A careful reading of the literature reveals several important themes. First, PBM does appear to exert real and reproducible biologic effects, particularly in reducing inflammation and promoting tissue repair. This is supported by multiple controlled trials in conditions such as mucositis and chronic wounds.
Second, the effects are highly dependent on treatment parameters. Wavelength, energy density, duration, and frequency all influence outcomes, and these variables differ widely across studies. This lack of standardization makes it difficult to generalize findings or develop uniform clinical protocols.
Third, the magnitude of benefit is typically modest. PBM is best understood as an adjunctive therapy—one that may enhance healing or reduce symptoms, but rarely replaces standard treatments.
Finally, the strength of evidence varies by condition. While some indications are supported by high-level data, others rely on small or heterogeneous studies, limiting confidence in their clinical applicability.
What We Still Have Yet to Learn
Despite growing interest, there are significant gaps in our understanding of PBM—particularly in pediatric populations.
Most notably, pediatric-specific data are limited outside of oncology-related mucositis. Long-term safety data are sparse, and the cumulative effects of repeated exposure over years remain unclear. In addition, optimal dosing parameters have not been standardized, even within adult populations.
Another challenge lies in the variability of devices. Many PBM products are marketed as general wellness tools and do not require rigorous clinical trials prior to release. This creates a disconnect between controlled research environments and real-world use, where families may be using devices with unknown specifications or inconsistent output.
Future research will need to address these gaps—particularly through well-designed pediatric trials and comparative studies that help define optimal treatment parameters.
Potential Side Effects and Pediatric Safety Considerations
One of the primary reasons for the growing popularity of PBM is its favorable safety profile. Most reported adverse effects are mild and transient, including erythema, irritation, or a sensation of warmth. More significant reactions, such as blistering or pigmentation changes, are uncommon but have been described.
In pediatric care, several additional considerations are important. Eye protection is essential, particularly with facial devices, due to the potential for retinal exposure. Skin response may vary by phenotype, with individuals of darker skin types potentially at increased risk for dyspigmentation, suggesting a need for more conservative dosing.
It is also important to recognize that PBM follows a biphasic dose-response curve. Insufficient dosing may be ineffective, while excessive exposure may reduce benefit or increase adverse effects. This challenges the common assumption that more frequent or longer treatments will yield better results.
Devices Commonly Used
PBM devices are available in a wide range of formats, reflecting both clinical and consumer markets. In medical settings, calibrated laser or LED systems are used. At home, families may encounter handheld devices, panels, facial masks, or helmet-style systems for hair growth.
Treatment sessions are typically brief—ranging from a few minutes to about 20 minutes—and are repeated several times per week over weeks to months. However, the variability in device quality and dosing parameters makes it difficult to ensure consistent outcomes outside of controlled settings.
Integrating Red Light Therapy into Pediatric Practice
Red light therapy occupies a nuanced space within integrative pediatrics. It is neither fringe nor fully established. It offers biologic plausibility and meaningful evidence in specific contexts, but it is also subject to overextension in popular discourse.
For pediatricians, a balanced approach is warranted. PBM may be reasonably considered as an adjunctive therapy in select situations—particularly mucositis, wound healing, and possibly acne in adolescents—where the evidence supports benefit and the risk profile is low.
At the same time, broader systemic claims should be approached with caution. Our role is not only to evaluate therapies, but to help families interpret them—grounding decisions in evidence while remaining open to emerging modalities.
Red light therapy may ultimately secure a more defined role in pediatric care. For now, it represents a promising but evolving tool—one that invites both curiosity and clinical discernment.
References
Son Y, Lee H, Yu S, et al. Effects of photobiomodulation on multiple health outcomes: an umbrella review of randomized clinical trials. Syst Rev. 2025;14:160. doi:10.1186/s13643-025-02902-3
Maghfour J, Ozog DM, Mineroff J, Jagdeo J, Kohli I, Lim HW. Photobiomodulation CME part I: Overview and mechanism of action. J Am Acad Dermatol. 2024;91(5):793-802. doi:10.1016/j.jaad.2023.10.073
Mineroff J, Maghfour J, Ozog DM, Lim HW, Kohli I, Jagdeo J. Photobiomodulation CME part II: Clinical applications in dermatology. J Am Acad Dermatol. 2024;91(5):805-815. doi:10.1016/j.jaad.2023.10.074